Evaluation of the circulating fraction of the HER-2/neu oncogene in patients with cervical cancer

Objective: To evaluate circulating HER-2/neu in cervical cancer patients prior to and following treatment.

Methods: Controls, and patients with either cervical dysplasia or cancer taken from an active gynecologic oncology service were evaluated for the expression of HER-2/neu in serum by ELISA before and following surgery, radiation, chemotherapy or combinations thereof. The resulant data was then evaluated for significance by either ANOVA or non-parametric testing.

Results: Mean differences were noted for patients with cervical cancer compared to controls. Patients with a good response to the chemotherapy indicated an increase in the serum oncogene, while those not responding either had no marked change or decreased the level of serum HER-2/neu.

Conclusions: As serum HER-2/neu is a membrane bound portion of the intact molecule, these results suggest that due to the induction of cell death and breakdown, the liberation of this fraction (increased levels in the serum), is a viable indicator of response to treatment in some patients. A more detailed examination of this possibility along with expanded correlation with tissue expression is required.

HER-2/neu; Cervical cancer; Serum

[1] Costa M. J., Walls J., Trelford J. D.: "c-erbB-2 oncoprotem overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but uot an independent prognostic marker because it occurs late in the disease". Am. J. Clin. Path., 1995, 104, 64.

[2] Ndubisi B., Sanz S., Lu L., Podczaski E., Benrubi G., Masood S.: "The prognostic value of HER-2/neu oncogene in cervical cancer". Ann. Clin. Lab. Sci., 1997, 27, 396.

[3] Mark H. F. L., Feldman D., Das S., Sun C-L., Samy M., Lathrop J.: "HER-2/neu oncogene amplification in cervical cancer studied by fluorescent in situ hybridization". Genet. Test, 1999, 3, 237.

[4] Sharma A., Pratap M., Sawhney V. M., Khan I. U., Bhambhani S., Mitra A. B.: "Frequent amplification of c-erebB2 (HER-2/Neuloncgogene in cervical carcinoma as detected by non-fluorescence in situ hybridization technique on paraffin sections". Oncology, 1999, 56, 83.

[5] Kersemaekeres A. M. F., Fleuren G. J., Kenter G. G., Lambert J., Van Den Brock C. M., Uljee S. M., et al.: "Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis" Clin. Can. Res., 1999, 5, 577.

[6] Molina R.,J o J.,F ilella X.,B ruix J.,C astells A.,H ague M.,et al. :"Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases". Tumor Biol., 1997, 18, 188.

[7] Cirisano F. D., Karlan B. Y.: "The role of the HER-2/neu oncogene in gynecologic cancers". J. Soc. Gynecol. Invest., 1996, 3, 99.

[8] Leitzel K., Teramoto Y., Konrad K., Chincilli V. M., Volgas G., Grossberg H., et al.: "Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer". J. Clin. Oncol., 1995,13, 1129.

[9] Fehm T., Maimonis P., Weitz S., Teramoto Y., Katalinic A., Jager W.: "Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapyy in node-positive breast cancer patients". Breast. Cancer Res. Treat., 1997, 43, 87.

[10] Mckenzie J.,D eSombre K. A.,B ast B. S.,H ollis D. R.,W hitaker R. S., Berchuck A., et al.: "Serum levels of HER-2/neu (C-erbB-2) correlate with overexpression of p 185 in human ovarian cancer". Cancer, 1993, 71, 3942.

[11] Meden H., Marx D., Fattahi A., Rath W., Kron M., Wuttke W., et al.: "Elevated serum levels of c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy". J. Cancer Res. Clin. Oncol., 1994, 120, 378.

[12] Zabecky J. R., Lam T., McKenzie S. J., Cerney W.: "The extracellular domain of p 185/neu is released from the surface of human breast carcinoma cells SK-BR-3". J. Biol. Chem., 1991, 266, 1716.

[13] Meden H., Marx D., Schauer A., Wuttke W., Huhn W.: "Prognostic significance of p 1505 (c-erbB-2, HER-2/neu) serum levels in patients with ovarian cancer". Anticancer Res., 1999, 17, 757.

[14] Cheung T. H., Wong Y. F., Chung T. K. H., Maimonis P., Chang A. M.: "Clinical use of serum c-erbB-2 in patients with ovarian masses". Gynecol. Ohstet. Invest., 1999, 48, 133.

[15] Klapper L. N., Glathe S., Vaisman N., Hynes N. E., Andrews G C., Sela M., et al.: "The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors". Proc. natl. Acad. Sci. USA, 1999, 96, 4995.

[16] Bendstein B., Daxenbichler G., Windbichler G., Zeimet A. G., Geurts A., Sweep F., et al.: "Predictive value of PA, PAI-I, HER-2 and VEGF in the serum of ovarian cancer patients". Anticancer Res., 2000, 20, 569.

[17] Nijman H. W., Kenemans P., Poort-Keesom R. J., Verstraeten R A., Mensdorff-Pouilly S., Verheijen S., et al.: "Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer". Eur. J. Obstet. Gynecol. Reprod. Biol., 1999, 83, 201.

[18] Nakano T., Oka K., Ishikawa A., Morita S.: "Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma". Cancer, 1997, 79, 513.

[19] Volas G. H., Leitzel K., Teramoto Y., Grossberg H., Demers L., Lipton A.: "Serial serum c-erB-2 levels in patients with breast carcinoma". Cancer, 1996, 78, 267.